Key Points

  • Small-molecule GSIs increase BCMA surface expression on myeloma cells, resulting in enhanced CAR T-cell efficacy.

Abstract

B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc−/− mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA+ tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577.

REFERENCES

REFERENCES
1.
Attal
M
,
Harousseau
JL
,
Stoppa
AM
, et al
.
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome
.
N Engl J Med
.
1996
;
335
(
2
):
91
-
97
.
2.
Barlogie
B
,
Kyle
RA
,
Anderson
KC
, et al
.
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in J Clin Oncol. 2006;24(17):2687]
.
J Clin Oncol
.
2006
;
24
(
6
):
929
-
936
.
3.
Bladé
J
,
Rosiñol
L
,
Cibeira
MT
,
Rovira
M
,
Carreras
E
.
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010
.
Blood
.
2010
;
115
(
18
):
3655
-
3663
.
4.
Child
JA
,
Morgan
GJ
,
Davies
FE
, et al;
Medical Research Council Adult Leukaemia Working Party
.
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
.
N Engl J Med
.
2003
;
348
(
19
):
1875
-
1883
.
5.
Harousseau
JL
,
Attal
M
,
Divine
M
, et al
.
Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma
.
Stem Cells
.
1995
;
13
(
suppl 2
):
132
-
139
.
6.
Scott
EC
,
Hari
P
,
Sharma
M
, et al
.
Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis
.
Biol Blood Marrow Transplant
.
2016
;
22
(
10
):
1893
-
1899
.
7.
Sonneveld
P
,
Avet-Loiseau
H
,
Lonial
S
, et al
.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
.
Blood
.
2016
;
127
(
24
):
2955
-
2962
.
8.
Chim
CS
,
Kumar
SK
,
Orlowski
RZ
, et al
.
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond [published correction appears in Leukemia. 2019;33(4):1058-1059]
.
Leukemia
.
2018
;
32
(
2
):
252
-
262
.
9.
Lonial
S
,
Boise
LH
,
Kaufman
J
.
How I treat high-risk myeloma
.
Blood
.
2015
;
126
(
13
):
1536
-
1543
.
10.
Kumar
SK
,
Lee
JH
,
Lahuerta
JJ
, et al;
International Myeloma Working Group
.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153]
.
Leukemia
.
2012
;
26
(
1
):
149
-
157
.
11.
Palumbo
A
,
Anderson
K
.
Multiple myeloma
.
N Engl J Med
.
2011
;
364
(
11
):
1046
-
1060
.
12.
Brentjens
RJ
,
Davila
ML
,
Riviere
I
, et al
.
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
.
Sci Transl Med
.
2013
;
5
(
177
):
177ra38
.
13.
Maude
SL
,
Frey
N
,
Shaw
PA
, et al
.
Chimeric antigen receptor T cells for sustained remissions in leukemia
.
N Engl J Med
.
2014
;
371
(
16
):
1507
-
1517
.
14.
Turtle
CJ
,
Hanafi
LA
,
Berger
C
, et al
.
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
.
Sci Transl Med
.
2016
;
8
(
355
):
355ra116
.
15.
Kalos
M
,
Levine
BL
,
Porter
DL
, et al
.
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
.
Sci Transl Med
.
2011
;
3
(
95
):
95ra73
.
16.
Turtle
CJ
,
Hay
KA
,
Hanafi
LA
, et al
.
Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib
.
J Clin Oncol
.
2017
;
35
(
26
):
3010
-
3020
.
17.
Kochenderfer
JN
,
Dudley
ME
,
Kassim
SH
, et al
.
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
.
J Clin Oncol
.
2015
;
33
(
6
):
540
-
549
.
18.
Avery
DT
,
Kalled
SL
,
Ellyard
JI
, et al
.
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
.
J Clin Invest
.
2003
;
112
(
2
):
286
-
297
.
19.
O’Connor
BP
,
Raman
VS
,
Erickson
LD
, et al
.
BCMA is essential for the survival of long-lived bone marrow plasma cells
.
J Exp Med
.
2004
;
199
(
1
):
91
-
98
.
20.
Seckinger
A
,
Delgado
JA
,
Moser
S
, et al
.
Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment
.
Cancer Cell
.
2017
;
31
(
3
):
396
-
410
.
21.
Thompson
JS
,
Schneider
P
,
Kalled
SL
, et al
.
BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population
.
J Exp Med
.
2000
;
192
(
1
):
129
-
135
.
22.
Rennert
P
,
Schneider
P
,
Cachero
TG
, et al
.
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth
.
J Exp Med
.
2000
;
192
(
11
):
1677
-
1684
.
23.
Jelinek
DF
,
Darce
JR
.
Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors
.
Curr Dir Autoimmun
.
2005
;
8
:
266
-
288
.
24.
Novak
AJ
,
Darce
JR
,
Arendt
BK
, et al
.
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
.
Blood
.
2004
;
103
(
2
):
689
-
694
.
25.
Moreaux
J
,
Legouffe
E
,
Jourdan
E
, et al
.
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
.
Blood
.
2004
;
103
(
8
):
3148
-
3157
.
26.
Ali
SA
,
Shi
V
,
Maric
I
, et al
.
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
.
Blood
.
2016
;
128
(
13
):
1688
-
1700
.
27.
Brudno
JN
,
Maric
I
,
Hartman
SD
, et al
.
T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma
.
J Clin Oncol
.
2018
;
36
(
22
):
2267
-
2280
.
28.
Cohen
AD
,
Garfall
AL
,
Stadtmauer
EA
, et al
.
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
.
J Clin Invest
.
2019
;
129
(
6
):
2210
-
2221
.
29.
Raje
N
,
Berdeja
J
,
Lin
Y
, et al
.
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma
.
N Engl J Med
.
2019
;
380
(
18
):
1726
-
1737
.
30.
Grupp
SA
,
Kalos
M
,
Barrett
D
, et al
.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
.
N Engl J Med
.
2013
;
368
(
16
):
1509
-
1518
.
31.
O’Rourke
DM
,
Nasrallah
MP
,
Desai
A
, et al
.
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
.
Sci Transl Med
.
2017
;
9
(
399
):
32.
Fry
TJ
,
Shah
NN
,
Orentas
RJ
, et al
.
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
.
Nat Med
.
2018
;
24
(
1
):
20
-
28
.
33.
Laurent
SA
,
Hoffmann
FS
,
Kuhn
PH
, et al
.
γ-Secretase directly sheds the survival receptor BCMA from plasma cells
.
Nat Commun
.
2015
;
6
:
7333
.
34.
Golde
TE
,
Koo
EH
,
Felsenstein
KM
,
Osborne
BA
,
Miele
L
.
γ-Secretase inhibitors and modulators
.
Biochim Biophys Acta
.
2013
;
1828
(
12
):
2898
-
2907
.
35.
Yuan
X
,
Wu
H
,
Xu
H
, et al
.
Notch signaling: an emerging therapeutic target for cancer treatment
.
Cancer Lett
.
2015
;
369
(
1
):
20
-
27
.
36.
Salter
AI
,
Ivey
RG
,
Kennedy
JJ
, et al
.
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
.
Sci Signal
.
2018
;
11
(
544
):
37.
Hudecek
M
,
Lupo-Stanghellini
MT
,
Kosasih
PL
, et al
.
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
.
Clin Cancer Res
.
2013
;
19
(
12
):
3153
-
3164
.
38.
Hudecek
M
,
Sommermeyer
D
,
Kosasih
PL
, et al
.
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity
.
Cancer Immunol Res
.
2015
;
3
(
2
):
125
-
135
.
39.
Gogishvili
T
,
Danhof
S
,
Prommersberger
S
, et al
.
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
.
Blood
.
2017
;
130
(
26
):
2838
-
2847
.
40.
Carpenter
RO
,
Evbuomwan
MO
,
Pittaluga
S
, et al
.
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma
.
Clin Cancer Res
.
2013
;
19
(
8
):
2048
-
2060
.
41.
Liu
L
,
Sommermeyer
D
,
Cabanov
A
,
Kosasih
P
,
Hill
T
,
Riddell
SR
.
Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy
.
Nat Biotechnol
.
2016
;
34
(
4
):
430
-
434
.
42.
Wang
X
,
Chang
WC
,
Wong
CW
, et al
.
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
.
Blood
.
2011
;
118
(
5
):
1255
-
1263
.
43.
Sommermeyer
D
,
Hill
T
,
Shamah
SM
, et al
.
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
.
Leukemia
.
2017
;
31
(
10
):
2191
-
2199
.
44.
Riddell
SR
,
Greenberg
PD
.
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells
.
J Immunol Methods
.
1990
;
128
(
2
):
189
-
201
.
45.
Salem
DA
,
Maric
I
,
Yuan
CM
, et al
.
Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma
.
Leuk Res
.
2018
;
71
:
106
-
111
.
46.
Massard
C
,
Azaro
A
,
Soria
JC
, et al
.
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
.
Ann Oncol
.
2018
;
29
(
9
):
1911
-
1917
.
47.
Ghermezi
M
,
Li
M
,
Vardanyan
S
, et al
.
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
.
Haematologica
.
2017
;
102
(
4
):
785
-
795
.
48.
Watanabe
K
,
Terakura
S
,
Martens
AC
, et al
.
Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells
.
J Immunol
.
2015
;
194
(
3
):
911
-
920
.
49.
Sotillo
E
,
Barrett
DM
,
Black
KL
, et al
.
Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy
.
Cancer Discov
.
2015
;
5
(
12
):
1282
-
1295
.
50.
Rapoport
AP
,
Stadtmauer
EA
,
Binder-Scholl
GK
, et al
.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
.
Nat Med
.
2015
;
21
(
8
):
914
-
921
.
51.
Eagar
TN
,
Tang
Q
,
Wolfe
M
,
He
Y
,
Pear
WS
,
Bluestone
JA
.
Notch 1 signaling regulates peripheral T cell activation
.
Immunity
.
2004
;
20
(
4
):
407
-
415
.
52.
Debeb
BG
,
Cohen
EN
,
Boley
K
, et al
.
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells
.
Breast Cancer Res Treat
.
2012
;
134
(
2
):
495
-
510
.
53.
Walker
AJ
,
Majzner
RG
,
Zhang
L
, et al
.
Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase
.
Mol Ther
.
2017
;
25
(
9
):
2189
-
2201
.
54.
Lyu
MA
,
Cheung
LH
,
Hittelman
WN
,
Marks
JW
,
Aguiar
RC
,
Rosenblum
MG
.
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA
.
Mol Cancer Ther
.
2007
;
6
(
2
):
460
-
470
.
55.
Ramadoss
NS
,
Schulman
AD
,
Choi
SH
, et al
.
An anti-B cell maturation antigen bispecific antibody for multiple myeloma
.
J Am Chem Soc
.
2015
;
137
(
16
):
5288
-
5291
.
56.
Tai
YT
,
Mayes
PA
,
Acharya
C
, et al
.
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
.
Blood
.
2014
;
123
(
20
):
3128
-
3138
.
57.
Varga
C
,
Laubach
JP
,
Anderson
KC
,
Richardson
PG
.
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma
.
Br J Haematol
.
2018
;
181
(
4
):
433
-
446
.
58.
Sanchez
E
,
Gillespie
A
,
Tang
G
, et al
.
Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma
.
Clin Cancer Res
.
2016
;
22
(
13
):
3383
-
3397
.
59.
Tolcher
AW
,
Messersmith
WA
,
Mikulski
SM
, et al
.
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
.
J Clin Oncol
.
2012
;
30
(
19
):
2348
-
2353
.
60.
Pisklakova
A
,
Grigson
E
,
Ozerova
M
,
Chen
F
,
Sullivan
DM
,
Nefedova
Y
.
Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment
.
Cancer Biol Ther
.
2016
;
17
(
5
):
477
-
485
.
61.
Giavridis
T
,
van der Stegen
SJC
,
Eyquem
J
,
Hamieh
M
,
Piersigilli
A
,
Sadelain
M
.
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
.
Nat Med
.
2018
;
24
(
6
):
731
-
738
.
62.
Norelli
M
,
Camisa
B
,
Barbiera
G
, et al
.
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
.
Nat Med
.
2018
;
24
(
6
):
739
-
748
.
You do not currently have access to this content.